G. Garcia‐Manero

发表

The role of TGFβ in hematopoiesis and myeloid disorders

G. Garcia-Manero, K. Soltysiak, G. Montalban-Bravo, 2019, Leukemia.

Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panels

F. Meric-Bernstam, G. Garcia-Manero, M. Routbort, 2018, Cancer.

Phase I and pharmacokinetic study of a low‐clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004, Cancer.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2019, The Lancet. Haematology.

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

T. Kadia, R. Kanagal-Shamanna, L. Medeiros, 2022, Leukemia.

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).

P. Campbell, M. Cazzola, D. Neuberg, 2020, Blood.

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

MYELOID NEOPLASIA TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

D. Neuberg, B. Ebert, P. Stojanov, 2014 .

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Scott E. Smith, G. Garcia-Manero, D. Steensma, 2012, Journal of Hematology & Oncology.

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes

G. Garcia-Manero, M. Routbort, K. Patel, 2022, Modern Pathology.